HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. - Wikidata - wikimedia - TriplyDB

HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer.

HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer.

http://www.wikidata.org/entity/Q37080967

about

Emerging therapeutic biomarkers in endometrial cancer Chemoresistance and targeted therapies in ovarian and endometrial cancers Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical Dilemmas The epidermal growth factor receptor critically regulates endometrial function during early pregnancy.Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?EGFR isoforms and gene regulation in human endometrial cancer cells Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis.The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer The genomics and genetics of endometrial cancer.p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans.Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer.Molecular determinants for lymph node metastasis in clinically early-stage endometrial cancer.NMU signaling promotes endometrial cancer cell progression by modulating adhesion signaling.A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study Personalized care in uterine cancer.The important application of thioridazine in the endometrial cancer.Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas.Molecular pathogenesis of endometrial and ovarian cancer.Systematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience Genomic characterization of gene copy-number aberrations in endometrial carcinoma cell lines derived from endometrioid-type endometrial adenocarcinoma Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.Unresolved issues in the management of endometrial cancer.Emerging therapeutic targets in endometrial cancer.Update on prognostic markers for endometrial cancer.Emerging drugs for endometrial cancer.Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation.Coordinated targeting of the EGFR signaling axis by microRNA-27a*.Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.Targeted endometrial cancer therapy as a future prospect.Discordant Mutations in Paired Primary and Metastatic Endometrial Adenocarcinomas Identified by Semiconductor-Based Sequencing for Rapid Cancer Genotyping.Molecular diagnosis of endometrial cancer from uterine aspirates.A novel algorithm for network-based prediction of cancer recurrence.Next-Generation Sequencing.Tumor-associated macrophages are correlated with tamoxifen resistance in the postmenopausal breast cancer patients.Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma.The paradoxical functions of EGFR during breast cancer progression Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late

P2860

Q26865904-C44640EE-7AAA-42B3-9331-9D970B725D65 Q28073246-1570F497-1452-43DA-8EA2-D2AE91B4A530 Q28074769-D0792650-4CED-4A20-A8CA-50821DF20B19 Q30412338-0E4C0E2E-50B8-495E-BD16-94454474D83B Q33633962-B441C61A-9E15-452C-AB58-650D63BA64E1 Q34008570-AAFDA68F-4138-4F83-A935-D3815384C72F Q35870242-42A02754-0FB0-47BE-A79D-427B2A894629 Q35879733-75AF3DAB-5B54-42FA-B240-FC3564CC2437 Q36064912-892875BF-A4FF-4EC2-B556-695244306355 Q36151896-2B7A768C-90B2-4864-A94C-F645FD9530F0 Q36386468-E93397DE-2CEA-4C42-9BE9-74B45F9E6F21 Q36456386-4AC35BBF-2D2B-45CC-8FDA-8708FBD89596 Q36471479-E7D41902-D6FB-4497-8A8D-00D9428325B0 Q36502473-CD1739F1-67C9-4B36-80D1-39ADC2FDBCD5 Q36962930-1B2E0BA7-7F6E-43CC-A1A4-60E4D1A46115 Q36980484-BE6C87C2-CF88-4A4C-A6F0-112A260F43FE Q37006856-541B5FA5-374A-44ED-81A7-B3875477E1B3 Q37060799-70075825-C44D-4C17-B22B-855B5F709D2D Q37091691-A2243A24-F5F1-4AD5-B910-5CA26BB7E90B Q37293672-BDB94D5E-9648-459D-A2DA-D7E85413B5A8 Q37359309-6969B1C7-8D78-4635-AFCD-BD41A43A128E Q37432375-09FD24C7-EBA9-4FF5-A9AF-56B8CC572A13 Q37671783-967E4695-410D-4495-A063-2C63D3064352 Q37821897-B31B1592-B260-4AE5-838F-7AD1307A5AC4 Q37827340-19495274-93ED-49BE-8926-DBF00924B11F Q38222517-AEFFD1FE-E73C-4D73-9A0F-27CD7F2DBFBF Q38261469-018CEAE2-F520-49CD-AF1A-F566923B8F15 Q38895754-B178FC8F-B9E0-45C9-B83A-4587AE442BDB Q38984603-5CB13FF6-0973-464C-89C3-5467E6B41769 Q39107545-9D827DE3-923C-4A37-BF33-4F660E67B53F Q39123683-F63F432C-02ED-4576-AFC1-26BC374231A2 Q39454208-4723DD4D-72E3-4D64-8BC3-46A0AF8D7127 Q39773144-901129AD-C90C-4A12-8417-4AAABC7E5D0E Q44593249-1E56A192-0977-4527-A579-972E00E8F91D Q50605014-A097A9A3-36F7-43A1-8E66-77460E6F7CE2 Q51032285-B6F5C0AE-19F9-40AC-889F-A24696745DED Q54384989-0F804ED3-02A2-41B0-AE32-49A592C7C978 Q54530132-44E44F75-4613-47B7-B22C-D2D9E584C4E9 Q57118645-BD2C5FB0-5E2C-4AC2-8F02-C0FEB942D64F Q57169683-FFDDB981-F52A-4767-852F-62D3B99C178F

P2860

HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer.

http://www.wikidata.org/entity/Q37080967

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

HER2 gene amplification and EG ...... (type II) endometrial cancer.

@en

HER2 gene amplification and EG ...... patients with nonendometrioid

@nl

type

label

HER2 gene amplification and EG ...... (type II) endometrial cancer.

@en

HER2 gene amplification and EG ...... patients with nonendometrioid

@nl

prefLabel

HER2 gene amplification and EG ...... (type II) endometrial cancer.

@en

HER2 gene amplification and EG ...... patients with nonendometrioid

@nl

P1433

Q37080967-98FDEE48-E976-488B-B589-D8429EF4E16D

P1476

Q37080967-FFB0A22F-13D7-4349-A180-0BC655E6255E

P2093

Q37080967-1E8FAE29-F425-4140-B58E-4E0C41AEF8B7

Q37080967-34B64645-0938-431C-8C01-08F3FEE7A4DF

Q37080967-38022C59-0892-4861-A866-964D4874048C

Q37080967-3EA056D9-747E-4E71-B19D-FA05A4CB1DE8

Q37080967-4D153AC0-B2AE-437A-81DD-7954C85E5FD7

Q37080967-6F646694-7E3C-4618-A3A1-D568A1E89E5A

Q37080967-76C362E7-E16A-4FDA-9A39-F105815B3359

Q37080967-82F4F6AD-EB96-4AED-AC3C-F64A2B85D74B

Q37080967-A237D706-C567-4F53-86EC-54678915A03B

Q37080967-B4A2410B-B053-4953-B536-8565C67CB9BF

P2860

Q37080967-0C6C5ABE-6B86-42B2-9C23-BD10217D8851

Q37080967-0D0ADC84-12D2-42CD-860D-1D6F7C63A152

Q37080967-148E8D5D-D2BD-46E8-A5EA-A66754B083CA

Q37080967-21805F3F-930B-4F8D-97B7-3EFEB843572B

Q37080967-35CE0EDB-799F-41C6-A56E-1C56ACE80027

Q37080967-4660E2C7-6CBA-4681-A37A-8BA70B413710

Q37080967-506320B6-E04D-4F3B-B8F6-539D75B30F9F

Q37080967-559C5CD8-5BB7-4F96-A09A-9AD0519BD7EB

Q37080967-5D9FD709-2E20-44CE-913E-3A344319E7E8

Q37080967-6D3C9BE4-984D-41FB-B6DD-5289E786628E

P2888

Q37080967-E365856B-4E69-4989-A78F-E5DD56BD3C05

P304

Q37080967-790AA214-3634-495C-867B-649D68454E78

P31

Q37080967-F1614235-097D-463B-B513-4533D6502FDB

P356

Q37080967-97620926-BF77-4566-9E62-1A4328599FE7

P407

Q37080967-6A0FC701-4C24-46CF-9D81-46CC02B58E04

P433

Q37080967-70282B97-E89D-46D6-A6DA-C696F69A54F5

P478

Q37080967-7DF5093A-DFF4-4D48-9388-4728FC922658

P577

Q37080967-2F0D4893-A816-4435-AF72-9C4D2CD4D094

P5875

Q37080967-2219B365-DE6E-4589-8F91-A1C31D0BDC52

P698

Q37080967-41EFAEBC-923B-494E-A145-F785831FA7BD

P921

Q37080967-8FA2EDB0-A9CB-4308-A106-9A21EAC5739A

P932

Q37080967-9CC2D48A-A522-45DC-8D41-1CEBB5E2B483

P356

P1433

British Journal of Cancer

P1476

HER2 gene amplification and EG ...... (type II) endometrial cancer.

@en

P2093

A Mariani

http://www.w3.org/2001/XMLSchema#string

B Thomas

http://www.w3.org/2001/XMLSchema#string

B Winterhoff

http://www.w3.org/2001/XMLSchema#string

C Neuper

http://www.w3.org/2001/XMLSchema#string

D Riehle

http://www.w3.org/2001/XMLSchema#string

G E Konecny

http://www.w3.org/2001/XMLSchema#string

G L Keeney

http://www.w3.org/2001/XMLSchema#string

H-J Wang

http://www.w3.org/2001/XMLSchema#string

K C Podratz

http://www.w3.org/2001/XMLSchema#string

L Muderspach

http://www.w3.org/2001/XMLSchema#string

P2860

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.

Treatment of uterine papillary serous carcinoma with paclitaxel.

Rare uterine cancers.

Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases.

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.

Molecular and pathologic aspects of endometrial carcinogenesis.

Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases.

P2888

P304

89-95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6604814

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23669604

http://www.w3.org/2001/XMLSchema#string

P698

19088718

http://www.w3.org/2001/XMLSchema#string

P921

P932

2634683

http://www.w3.org/2001/XMLSchema#string